Shots:

• Washington University will receive milestones along with royalties on future sales of each licensed compound if Eisai exercises its options. Eisai to get an option right to develop & commercialize any compounds & biomarkers
• The collaboration combines Washington University scientists’ expertise in the fundamental & clinical research for ND with Eisai’s extensive experience in drug discovery & development to develop multiple novel therapeutic candidates along with discovering and identifying biomarkers within the next 5yrs. with the use of human biology
• E2814 is being studied in the P-II/III (Tau NexGen Study) for dominantly inherited Alzheimer's disease (DIAD). The study was conducted by DIAN-TU & led by the University’s School of Medicine

Ref: Eisai | Image: Eisai